|Mr. John G. Melo||Pres, CEO & Director||1.15M||N/A||1966|
|Mr. Eduardo Alvarez||Chief Operating Officer||665.19k||N/A||1964|
|Ms. Kathleen Valiasek||Chief Bus. Officer||588.08k||N/A||1964|
|Mr. Hermanus Kieftenbeld||Chief Financial Officer||N/A||N/A||1966|
|Mr. Anthony Hughes||Chief Accounting Officer||N/A||N/A||1965|
|Mr. Peter DeNardo||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Nicole Kelsey||Gen. Counsel & Sec.||N/A||N/A||1966|
|Ms. Beth Baker Bannerman||Sr. VP of Corp. Communications & Engagement||N/A||N/A||N/A|
|Ms. Christine Ofori||Chief People Officer||N/A||N/A||N/A|
|Mr. Charles Kraft||Sr. VP of Global Manufacturing & Process Devel.||N/A||N/A||N/A|
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Amyris, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 8; Compensation: 10.